Viktoria Hjalmar1, Robert Hast, Eva Kimby. 1. Division of Hematology, Department of Medicine, Karolinska Hospital, Stockholm, Sweden. viktoria.hjalmar@ks.se
Abstract
BACKGROUND: Surface antigen expression can be used to define subgroups of patients with different clinical courses in chronic lymphocytic leukaemia of the B-cell type (CLL). PURPOSE- METHODS: To study the clinical significance of functional markers linked to proliferation (CD25), adhesion (CD54), and apoptosis (CD95) on B- and T-cells in 68 patients with CLL using dual colour flow cytometry (FCM). RESULTS: The mean proportion of CD19+ B-cells expressing CD25 was significantly higher in CLL patients compared to controls (P=0.02), while CD54+ and CD95+ B-cells did not differ significantly. In CLL with atypical morphology and in patients with trisomy 12, the mean percentage of CD25+ B-cells was lower than in typical CLL (P<0.02) and in patients with disomic tumor cells (P<0.03). Patients with 30% of CD25+ B-cells had a shorter median time to treatment than CD25-negative cases (P=0.01). A low CD54 expression was associated with a prolonged median time to treatment (P=0.004), low WBC counts (P<0.05), and low S-LDH (P=0.03). A high CD95 expression was correlated with elevated S-LDH (P=0.02) and a finding of lymphadenopathy (P=0.02). In individual patients there was a strong correlation between B- and T-cell expression of CD25 (P<0.0001), CD54 (P=0.0002), and CD95 (P=0.0002), respectively. CONCLUSIONS: CD25 and CD54 expression on CD19+ cells seems to give prognostic information. The strong correlation between the expression of CD25, CD54 and CD95 on B-and T-cells suggests that the expression of these antigens is not an inherent characteristic of the malignant B-cell clone.
BACKGROUND: Surface antigen expression can be used to define subgroups of patients with different clinical courses in chronic lymphocytic leukaemia of the B-cell type (CLL). PURPOSE- METHODS: To study the clinical significance of functional markers linked to proliferation (CD25), adhesion (CD54), and apoptosis (CD95) on B- and T-cells in 68 patients with CLL using dual colour flow cytometry (FCM). RESULTS: The mean proportion of CD19+ B-cells expressing CD25 was significantly higher in CLL patients compared to controls (P=0.02), while CD54+ and CD95+ B-cells did not differ significantly. In CLL with atypical morphology and in patients with trisomy 12, the mean percentage of CD25+ B-cells was lower than in typical CLL (P<0.02) and in patients with disomic tumor cells (P<0.03). Patients with 30% of CD25+ B-cells had a shorter median time to treatment than CD25-negative cases (P=0.01). A low CD54 expression was associated with a prolonged median time to treatment (P=0.004), low WBC counts (P<0.05), and low S-LDH (P=0.03). A high CD95 expression was correlated with elevated S-LDH (P=0.02) and a finding of lymphadenopathy (P=0.02). In individual patients there was a strong correlation between B- and T-cell expression of CD25 (P<0.0001), CD54 (P=0.0002), and CD95 (P=0.0002), respectively. CONCLUSIONS:CD25 and CD54 expression on CD19+ cells seems to give prognostic information. The strong correlation between the expression of CD25, CD54 and CD95 on B-and T-cells suggests that the expression of these antigens is not an inherent characteristic of the malignant B-cell clone.
Authors: Francesca M Rossi; Maria Ilaria Del Principe; Davide Rossi; Maria Irno Consalvo; Fabrizio Luciano; Antonella Zucchetto; Pietro Bulian; Riccardo Bomben; Michele Dal Bo; Marco Fangazio; Dania Benedetti; Massimo Degan; Gianluca Gaidano; Giovanni Del Poeta; Valter Gattei Journal: J Transl Med Date: 2010-03-08 Impact factor: 5.531